

Balance Sheet

As at 1 August 2025

	Notes	2025
Current Assets		
Cash at bank and in hand		402,750.32
Total Current Assets		402,750.32
Other debtors		0
Prepayments		92.11
Current Liabilities		0
Total Assets less Current Liabilities		402,842.43
Net Assets		<u>402,842.43</u>
Reserves		
Unrestricted Reserves		2,924.85
Restricted Reserves		402,054.48
Total Reserves		<u>404,979.33</u>

Approved by the Trustees on 28 May 2026 and signed on their behalf by:



Trustee

GARY SHIELDS

Statement of Financial Activities -Sidefxhub
Income and Expenditure
For the period ended 1 August 2025

	Unrestricted funds	Restricted funds	Total Funds
	to the nearest £	to the nearest £	to the nearest £
A1 Receipts			
UK Donations in GBP	2380	400000	402380
UK donations in Kind	0	0	
Non-UK donations in GBP	291		291
Bank Interest		31.48	31.48
Non-UK donations in Euros (GBP equivalent)	47.84		47.84
Sub total (gross income for AR)	2718.84	400031.48	402750.32
Total receipts	402750.32		
A3 Payments			
I.T & Computing	412.78		
Donations and Grants	755.69		
Bank & Payment Processing Fees	243.52		
Sub total	1411.99		
Total payments	1411.99		
Net of receipts/payments	1306.85	400031.48	401338.33
A5 Transfers between funds	0		
A6 Cash funds last year end	1618	2023	3641
Cash funds this year end	2924.85	402054.48	406391.32

Independent Examiner's/ Auditor's Report to the Trustees of Sidefxhub.UK

On accounts for the period ended	1 st August 2025	Charity no	1203385
----------------------------------	-----------------------------	------------	---------

Set out on pages	1 to 5
------------------	--------

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the period ended 01/08/2025.

Responsibilities and basis of report As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Signed: 

Date: 31 May 2026

Name: Max Retallack

Relevant professional qualification(s) or body (if any): FCCA

Address: Nelson House, 2 Hamilton Terrace,
Leamington Spa, Warwickshire
CV32 4LY


7. Trustee Responsibilities Statement

The Trustees (who also act as Directors for company law purposes) are responsible for preparing this report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (FRS 102). They must:


1. Select and apply suitable accounting policies consistently.
2. Observe the methods and principles in the Charities SORP.
3. Make reasonable and prudent judgments and estimates.
4. Prepare the financial statements on a going-concern basis unless inappropriate.
5. Maintain adequate accounting records and implement effective internal controls.

Approved by the Board of Trustees on 28 May 2026 and signed on its behalf

Robert Dixon, Chair



Gary Shields, Treasurer



be published by the end of 2026, with progress being made for the start of clinical trials

- **Stakeholder Collaboration:** Continued data-sharing frameworks with University of Milan and UK research partners for parallel studies are still being developed.
- **Public Awareness:** Extremely positive and extensive multiple media successes were made in this accounting period. TV, Radio and Press coverage reached many millions. The charity is now regularly receiving enquiries from media outlets for informed comment.,
- **Regulatory Engagement:** We continue to engage with the MHRA and other international drug regulatory agencies

Challenges:

We continue to struggle to secure repeat funding from a donor base that is largely financially compromised. At the same time, we must be mindful of the need for future projects, whilst managing reserves prudently and responsibly.

5. Financial Review

Funds carried forward:	£3,641
Total incoming resources:	£402,750.32
Total resources expended:	£1411.99
Net movement in funds:	£406,391.32
Cash funds carried forward:	£406,391.32

Reserves Policy:

Trustees aim to hold unrestricted reserves equivalent to approximately 12 months of running costs (c. £1,500). As at 1 August 2024, free reserves stood at £2,924.85, as trustees await decisions regarding future research donations.

Principal Funding Sources:

Individual donations, raised on the understanding that donors will not be placed in financial hardship by their contributions.

6. Plans for Future Periods

1. **Diversify Funding Base:** Target corporate donors, private philanthropic foundations and government grant programmes.
2. **Patient Database Project:** Secure core funding to develop a comprehensive patient registry to identify symptom-profile patterns and potential biomarkers.
3. **Digital Outreach:** Launch a YouTube channel to serve as an accessible information hub for PFS and PSSD communities.
4. **Political Engagement:** Lobby key MPs and form a cross-party group to influence men's and young people's health policy, enhancing submissions to regulators and scientific nomenclature bodies.

3. Objectives, Public Benefit and Activities

Charitable Objects:

To promote scientific research into the prevention, cure, management and alleviation of iatrogenic disease—including, but not limited to, Post-Finasteride Syndrome—by providing funding on the condition that useful research results are disseminated for public benefit.

Public Benefit:

The trustees confirm that they have had due regard to the Charity Commission's public benefit guidance in planning and delivering activities during the reporting period. By funding independent scientific research, raising awareness among healthcare professionals and the wider public, and facilitating improved adverse-effect reporting, the charity has continued to:

- Advance understanding of PFS/PSSD pathophysiology, benefiting current and future patients through peer-reviewed publications and data-sharing networks.
- Improve patient outcomes by disseminating practical information and resources, leading to earlier recognition and management of adverse effects by clinicians.
- Enhance regulatory safeguards by collaborating with the MHRA to refine adverse-event reporting workflows, reducing the risk of under-reporting and safeguarding public health.

Activities during 2 August 2024 – 1 August 2025:

- **Fundraising:** Raised £402,380, £400,000 of which is restricted by two anonymous donors, to be spent on research in progress and future potentially relevant projects. All donations are made in accordance with the Charity's documented donations policy. Funds are predominantly received from patients and family members.
- **Grant-making:** Committed approximately £750 to fund Professor Melcangi's "Milano Project" at the University of Milan, a seven-investigation initiative translating preclinical PFS findings toward human trials. Our trusted partner, The PFS Foundation, requested that we held off making a more substantial donation until after the accounting period to assist a joint fundraising initiative occurring later in the year.
- **Scientific Engagement:** We continued to search for and screen additional researchers to investigate underlying mechanisms of PFS and Post-SSRI Sexual Dysfunction (PSSD). A potential collaboration with the University of Glasgow is still in obedience.
- **Awareness and Advocacy:**
 - Orchestrated TV, radio and press interviews to highlight the scale and severity of finasteride side-effects.
 - Engaged the MHRA to improve adverse-effect reporting accuracy and timeliness.
 - Organised a specific outreach programme aimed at health professionals involved with those suffering from PFS and PSSD

4. Achievements and Performance

- **Research Funding:** Continued funding for two ongoing and five new clinical-translational studies within the Milano Project. Two peer-reviewed studies are due to

Sidefxhub.UK
Trustees' Annual Report for the period ending 1 August 2025
(Period: 2 August 2024 to 1 August 2025)

1. Reference and Administrative Details

- **Charity name:** Sidefxhub.UK
- **Registered charity number:** 1203385
- **Registered office:** 66 Leam Terrace, Leamington Spa, CV31 1BQ
- **Trustees who served during the period:**
 1. Gary Shields (Treasurer)
 2. Katharine Hayden (Scientific Officer)
 3. Bernard Morlet (Chair)
 4. Robert Dixon

(All trustee appointments are patient- or beneficiary-led, or involve family members of patients, recruited by invitation.)

- **Board of Directors:**

1. Gary Shields
2. Morten Skov
3. Robert Dixon
4. Bernard Morlet

(Patient- or family-member-led, meeting at least weekly with daily communication as needed.)

- **Key advisers:**

- **Independent Examiner:** Max Retallack, TC Group Business Advisors & Accountants
- **Bankers:**
 - The Co-operative Bank Community Direct Plus Account (online)
 - WISE Foreign Currency Account (online)

2. Structure, Governance and Management

Sidefxhub.UK is constituted as a Charitable Incorporated Organisation (CIO) under English law. Overall control is vested in the Board of Trustees, who set strategic direction and oversee governance. Day-to-day decision-making is delegated to a patient-led Board of Directors, which meets weekly (with continual and frequent daily liaison) to manage operations and put the trustees' policies into practice. A formal risk-register is maintained and reviewed quarterly, covering financial stability, safeguarding, and regulatory compliance.